trending Market Intelligence /marketintelligence/en/news-insights/trending/v_KrETzkJ03GcKLlPke6gg2 content esgSubNav
In This List

Sinopharm Group FY'18 profit up 4.7% YOY

Blog

Funding Social and Affordable Housing: A Credit Perspective

Blog

Global Capital Markets & SPAC Activity – H1 2021

Blog

Gauging Supply Chain Risk In Volatile Times

Blog

Insight Weekly: Banks' efficiency push; vacuuming carbon; Big Pharma diversity goals


Sinopharm Group FY'18 profit up 4.7% YOY

Shanghai-based Sinopharm Group Co. Ltd.'s profit for full year 2018 grew 4.7% year over year.

Profit attributable to equity holders of the parent reached 5.84 billion yuan, from 5.58 billion yuan in 2017.

Diluted EPS was 1.97 yuan, compared to 1.88 yuan a year earlier.

Revenue for the year ended Dec. 31, 2018, grew 11.7% to 344.53 billion yuan, from 308.35 billion in 2017.

Revenue from the company's pharmaceutical distribution segment, which represents 80.4% of the group's total revenue, grew 9.3% to 281.05 billion.

Sinopharm, a wholesaler and retailer of pharmaceutical and healthcare products, booked 2018 operating profit of 15.40 billion yuan, from 13.14 billion a year earlier.

As of March 22, US$1 was equivalent to 6.72 Chinese yuan.